Holen Sie sich die Stockscreener-App
47.41
0.49%
0.23
Vorhandelsmarkt:
47.15
-0.26
-0.55%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$47.18
Offen:
$47.3
24-Stunden-Volumen:
9.51M
Relative Volume:
0.76
Marktkapitalisierung:
$96.50B
Einnahmen:
$47.70B
Nettoeinkommen (Verlust:
$5.07B
KGV:
19.12
EPS:
2.48
Netto-Cashflow:
$14.58B
1W Leistung:
+0.42%
1M Leistung:
+7.19%
6M Leistung:
-20.48%
1J Leistung:
-5.09%
1-Tages-Spanne:
$47.04
$47.86
1-Wochen-Bereich:
$46.65
$47.86
52-Wochen-Spanne:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
47.41 | 96.03B | 47.70B | 5.07B | 14.58B | 2.48 |
|
LLY
Lilly Eli Co
|
735.19 | 656.73B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 426.69B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
211.92 | 371.68B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.64 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
85.48 | 210.11B | 63.43B | 16.42B | 14.72B | 6.49 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Combining machine learning predictions for Bristol Myers Squibb CompanyPortfolio Update Report & Expert Curated Trade Ideas - Newser
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
What is Bristol Myers Squibb Company s revenue forecastQuarterly Performance Summary & Reliable Entry Point Trade Alerts - خودرو بانک
PureTech Health Cash Runway Extended - The Motley Fool
Can machine learning forecast Bristol Myers Squibb Company Equity Right recoveryEarnings Recap Report & Technical Confirmation Trade Alerts - Newser
Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital - MSN
Is it time to cut losses on Bristol Myers Squibb Company Equity RightInsider Buying & Stepwise Trade Signal Guides - Newser
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
BMS’ WEE1 degrader BMS-986463 as a pan-cancer approach - BioWorld MedTech
Key resistance and support levels for Bristol Myers Squibb Company2025 Key Lessons & Step-by-Step Trade Execution Guides - Newser
Visual trend scoring systems applied to Bristol Myers Squibb Company Equity RightM&A Rumor & Low Risk Entry Point Tips - Newser
Risk vs reward if holding onto Bristol Myers Squibb Company Equity RightEarnings Growth Report & Growth Focused Stock Pick Reports - Newser
Long term hold vs stop loss in Bristol Myers Squibb Company Equity Right2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Bristol Myers Squibb Company Equity Right’s volatility index tracking explained2025 Market Outlook & Risk Managed Investment Signals - Newser
BMO Capital Maintains a Hold on Bristol-Myers Squibb (BMY) - Yahoo Finance
How to interpret RSI for Bristol Myers Squibb Company stockEarnings Risk Report & Fast Gain Stock Tips - Newser
Using data tools to time your Bristol Myers Squibb Company Equity Right exit2025 Key Lessons & Reliable Breakout Forecasts - Newser
Investors three-year losses continue as Bristol-Myers Squibb (NYSE:BMY) dips a further 3.2% this week, earnings continue to decline - Yahoo Finance
Layoff Tracker: Exelixis Cuts Go Beyond Pennsylvania, Include 71 at California HQ - BioSpace
Price action breakdown for Bristol Myers Squibb CompanyJuly 2025 Earnings & Safe Swing Trade Setups - Newser
Can momentum traders help lift Bristol Myers Squibb CompanyWeekly Market Outlook & Momentum Based Trading Ideas - Newser
What MACD signals say about Bristol Myers Squibb Company Equity RightMarket Sentiment Review & Fast Gain Stock Trading Tips - Newser
News impact scoring models applied to Bristol Myers Squibb CompanyEarnings Risk Summary & Daily Technical Forecast Reports - Newser
Real time social sentiment graph for Bristol Myers Squibb CompanyWeekly Risk Summary & AI Optimized Trading Strategy Guides - Newser
How to track smart money flows in Bristol Myers Squibb Company Equity RightJuly 2025 Update & AI Driven Price Predictions - Newser
Chart based exit strategy for Bristol Myers Squibb CompanyJuly 2025 Recap & Capital Protection Trade Alerts - Newser
Chart based analysis of Bristol Myers Squibb Company Equity Right trendsWeekly Investment Summary & Growth Oriented Trade Recommendations - Newser
Should you wait for a breakout in Bristol Myers Squibb CompanyJuly 2025 Opening Moves & Capital Protection Trade Alerts - Newser
Can Bristol Myers Squibb Company lead its sector in growth getLinesFromResByArray error: size == 0 - mustnews.co.kr
Discovery of dual molecular glue degrader BMS-986470 - BioWorld MedTech
What momentum shifts mean for Bristol Myers Squibb CompanyWeekly Market Outlook & Free Weekly Watchlist of Top Performers - Newser
Can Bristol Myers Squibb Company hit a new high this month2025 Buyback Activity & Expert Verified Stock Movement Alerts - Newser
Cantor Fitzgerald Cuts Bristol-Myers (BMY) Price Target, Keeps Neutral - Insider Monkey
Will Camzyos Strengthen BMY's Cardiovascular Portfolio? - Yahoo Finance
What data driven models say about Bristol Myers Squibb Company Equity Right’s futureJuly 2025 Highlights & Fast Moving Market Watchlists - Newser
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY) - Yahoo Finance
Order flow analysis tools used on Bristol Myers Squibb Company Equity RightMarket Movement Recap & Step-by-Step Trade Execution Guides - Newser
Signal strength of Bristol Myers Squibb Company stock in tech scannersJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
Analyzing Bristol Myers Squibb Company with multi timeframe chartsPortfolio Performance Report & Daily Volume Surge Trade Alerts - Newser
Is Bristol Myers Squibb Company stock bottoming outWeekly Trend Report & AI Powered Market Entry Ideas - Newser
Earnings visualization tools for Bristol Myers Squibb CompanyWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Published on: 2025-08-26 17:49:14 - beatles.ru
Using Ichimoku Cloud for Bristol Myers Squibb Company Equity Right technicalsJuly 2025 Summary & Low Drawdown Trading Strategies - Newser
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Should You Revisit Bristol-Myers Squibb Amid Uncertainty Over Pharma Tariffs in 2025? - Yahoo Finance
Business development leadership team - Bristol Myers Squibb
Is Bristol Myers Squibb Company impacted by rising rates2025 Price Action Summary & Daily Stock Trend Watchlist - theviewers.co.kr
Bristol-Myers Squibb Company (NYSE:BMY) is favoured by institutional owners who hold 82% of the company - Yahoo Finance
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now? - Yahoo Finance
Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders - fiercebiotech.com
ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.20%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):